everolimus

News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

everolimus
Sep 26, 2024, 14:22 | Blog
Luis Castelo-Branco: Belzutifan vs everolimus for advanced kidney cancer
Luis Castelo-Branco shared a post on X: ''Belzutifan vs everolimus for advanced kidney cancer: NO…
Sep 19, 2024, 14:21 | Insight
Guilherme Nader Marta: Evergreen study led by Diogo Martins Branco
Guilherme Nader Marta, Oncology Fellow at Jules Bordet Institute, shared on X: “EVERGREEN study led…
Sep 14, 2024, 15:38 | Insight
ESMO24 Day 1 highlights by Tom Powles
The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona. ESMO24…
Sep 14, 2024, 11:04 | Blog
Dr. Andrea Apolo's highlights from ESMO24 - Day 1
24th European Society for Medical Oncology (ESMO) Congress, a major event in the field of…
Sep 10, 2024, 14:54 | Blog
Tom Powles: Belzutifan for clear cell renal cancer
Tom Powles shared a post on X: “Belzutifan significantly outperformed Everolimus in heavily pretreated clear…
Sep 8, 2024, 05:26 | Insight
Ahmed Nada: Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions
Ahmed Nada, Researcher at Global Alliance of Young Researchers, shared on LinkedIn: “Our Study titled:…
Aug 26, 2024, 20:08 | Insight
Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer
Tom Powles, Professor of urology cancer at the University of London and the Director of…
Aug 25, 2024, 13:02 | Insight
Toni Choueiri: Results from LITESPARK-005 are out
Toni Choueiri shared a post on X about a recent paper titled "Belzutifan versus Everolimus…
Aug 23, 2024, 14:26 | Insight
Amol Akhade: Belzutifan vs Everolimus for advanced RCC second line post IO plus TKI
Amol Akhade shared on LinkedIn: "Belzutifan vs Everolimus for advanced RCC second line post IO…
Jun 13, 2024, 03:19 | Drugs
Amol Akhade: Everolimus vs Alpelisib vs Capivasertib
Amol Akhade, Consultant Medical Oncologist atSuyog Cancer Clinics, shared a post on X: “Everolimus vs…
Jun 5, 2024, 01:48 | Societies
Toni Choueiri: Poster 269 by our super star Eddy Saad at ASCO24
Toni Choueiri shared a post on X: “Poster American Society of Clinical Oncology (ASCO24) 269 by…
May 26, 2024, 06:02 | Insight
Toni Choueiri: The work of Eddy Saad, Eli Van Allen, Sasha Gusev being highlighted here at ASCO24
Toni Choueiri shared a post by Neeraj Agarwal on X/Twitter: "The work of Eddy Saad, Eli Van…
Apr 22, 2024, 15:26 | Blog
Olubukola Ayodele: Attending the IKCS Europe 2024 conference in the picturesque seaside town of Sitges
Olubukola Ayodele, Consultant Medical Oncologist at Leicester Cancer Research Centre, shared on LinkedIn: "I'm currently attending…
Apr 14, 2024, 03:52 | Drugs
Piotr Wysocki: CLEAR trial – another study demonstrating that Immunotherapy and TKI combination should not be routinely recommended to favorable-risk RCC patients
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 23, 2024, 04:35 | Insight
Piotr Wysocki: How can we optimize the endocrine treatment of advanced HR+/HER2- breast cancer?
Piotr Wysocki, Professor of Medicine, Head of Department of Oncology at Jagiellonian University Hospital, recently…
Mar 14, 2024, 19:28 | Drugs
François-Clément Bidard: A prospective study to document the efficacy of the combo Fulvestrant+Everolimus
Erika Hamilton, Director of Breast Cancer and Gynecologic Cancer Research at Sarah Cannon Research Institute, shared…
Dec 14, 2023, 16:23 | Insight
SABCS23 Day 1 Highlights by Oncology Brothers
Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day's…
Oct 21, 2023, 14:04 | Drugs
Tom Powles: Renal cancer highlights ESMO23
Tom Powles Director of Barts Cancer Centre, shared a post on LinkedIn, saying: "Renal cancer…
All: 18 Posts: 1 - 100
Special Coverage